1-3 of 3
Ruwanthi N. Gunawardane
Close
Sort by
Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD
Journal: Blood
Blood (2009) 114 (22): 636.
https://doi.org/10.1182/blood.V114.22.636.636
Published: 2009
Journal Articles

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith W. Pratz, Gabriel Pallares, Qi Chao, Kelly G. Sprankle, Hitesh K. Patel, Mark Levis, Robert C. Armstrong, Joyce James, Shripad S. Bhagwat
Journal: Blood
Blood (2009) 114 (14): 2984–2992.
https://doi.org/10.1182/blood-2009-05-222034
Published: 2009
Includes: Supplemental data
Journal Articles

AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Patrick P Zarrinkar, PhD, Robert C Armstrong, Ph.D., Ruwanthi N Gunawardane, Ph.D., Joyce James, PhD, Mazen W Karaman, Ph.D., Shripad S Bhagwat, PhD
Journal: Blood
Blood (2008) 112 (11): 859.
https://doi.org/10.1182/blood.V112.11.859.859
Published: 2008